Network-based Approach in Type 2 Diabetes and Its Cardiovascular Risk
NCT ID: NCT03792607
Last Updated: 2019-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
35 participants
OBSERVATIONAL
2019-02-14
2020-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardioprotective Effect of SGLT2-I in Diabetic Patients With AMI (SGLT2-I AMI PROTECT Study)
NCT05261867
Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications
NCT07250607
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
NCT03786406
Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
NCT05363761
Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.
NCT04176276
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Clinical Diagnosis of macrovascular dysfunction.
• Patients with known history of cancer, malignancy disorders, active infections, and chronic or immune-mediated diseases.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Giuditta Benincasa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giuditta Benincasa
Principal Investigator GIUDITTA BENINCASA
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuditta Benincasa, MSc
Role: PRINCIPAL_INVESTIGATOR
Clinical Department of Internal Medicine and Specialistics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Università della Campania Luigi Vanvitelli
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Claudio Napoli, Professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Giuditta Benincasa, MSc
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Benincasa G, Franzese M, Schiano C, Marfella R, Miceli M, Infante T, Sardu C, Zanfardino M, Affinito O, Mansueto G, Sommese L, Nicoletti GF, Salvatore M, Paolisso G, Napoli C. DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study. Ann Med Surg (Lond). 2020 Oct 20;60:218-226. doi: 10.1016/j.amsu.2020.10.016. eCollection 2020 Dec.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRC-2015-2360454
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.